

This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies.

Enhanced Generation of Reactive Species by Cold Plasma in Gelatin Solutions for Selective Cancer Therapy

Journal:	<i>ACS Applied Materials & Interfaces</i>
Manuscript ID	Draft
Manuscript Type:	Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Labay, Cedric; Universitat Politecnica de Catalunya Roldan, Marcel; Universitat Politecnica de Catalunya Tampieri, Francesco; Universitat Politecnica de Catalunya, Department of Materials Science and Metallurgy Stacampiano, Augusto; GREMI Escot Bocanegra, Pablo; GREMI Ginebra, Maria-Pau; Universitat Politecnica de Catalunya, Department of Materials Science and Metallurgical Engineering Canal, Cristina; Universitat Politecnica de Catalunya, Materials Science and Engineering Department

SCHOLARONE™
Manuscripts

Enhanced Generation of Reactive Species by Cold Plasma in Gelatin Solutions for Selective Cancer Therapy

Cédric Labay^{1,2,3}, Marcel Roldán^{1,2}, Francesco Tampieri^{1,2,3}, Augusto Stancampiano⁴, Pablo Escot Bocanegra⁴, Maria-Pau Ginebra^{1,2,3,5}, Cristina Canal^{1,2,3}

¹ Biomaterials, Biomechanics and Tissue Engineering Group, Universitat Politècnica de Catalunya (UPC), Av. Eduard Maristany 10-14, 08019 Barcelona, Spain

² Barcelona Research Center in Multiscale Science and Engineering, UPC, Barcelona, Spain

³ Research Centre for Biomedical Engineering (CREB), UPC, 08019 Barcelona, Spain

⁴ GREMI, UMR 7344, CNRS/Université d'Orléans, BP 6744, CEDEX 2, 45067 Orléans, France

⁵ Institute for Bioengineering of Catalonia (IBEC), c/ Baldori i Reixach 10-12, 08028 Barcelona, Spain

Corresponding author: cristina.canal@upc.edu

ABSTRACT

Atmospheric pressure plasma jets generate reactive oxygen and nitrogen species (RONS) in liquids and biological media, which find application in the new area of plasma medicine. These plasma-treated liquids demonstrated recently to possess selective properties on killing cancer cells and attract attention towards new plasma-based cancer therapies. These allow for local delivery by injection in the tumor but can be quickly washed away by body fluids. By confining these RONS in a suitable biocompatible delivery system, great perspectives can be opened in the design of novel biomaterials aimed for cancer therapies. Gelatin solutions are evaluated here to store RONS generated by atmospheric pressure plasma jets, and their release properties are evaluated. The concentration of RONS was studied in 2% gelatin as a function of different plasma parameters (treatment time, nozzle distance and gas flow) with two different plasma jets. Much higher production of reactive species (H_2O_2 and NO_2^-) was revealed in the polymer solution than in water after plasma treatment. The amount of RONS generated in gelatin is greatly improved with respect to water, with concentrations of H_2O_2 and NO_2^- between 2 and 12 times higher for the longest plasma treatments. Plasma-treated gelatin exhibited the release of these RONS to a liquid media, which induced an effective killing of bone cancer cells. Indeed, *in vitro* studies on Sarcoma Osteogenic (SaOS-2) cell line exposed to plasma-treated gelatin lead to time-dependent increasing cytotoxicity with the longer plasma treatment time of gelatin. While SaOS-2 cell viability decreased down to 12%-23% after 72 hours for cells exposed to 3-min treated gelatin, viability of healthy cells (hMSC) was preserved (around 90%), establishing the selectivity of the plasma-treated gelatin on cancer cells. This sets the basis for designing improved hydrogels with high capacity to deliver RONS locally to tumors.

Keywords: Cold atmospheric plasma; hydrogel; osteosarcoma; reactive oxygen and nitrogen species.

1. INTRODUCTION

The potential of targeting the oxidative stress response in cancer cells that could overcome drug resistance and spare normal tissue is being investigated as novel treatment by different techniques. Production of reactive oxygen and nitrogen species (RONS) in liquids (water, saline solutions, cell culture media) by treatment with cold atmospheric plasmas has been focus of interest in the last years due to its implications in biology and medicine (i.e. from wound healing to cancer treatment). Thus, the generation of species such as H_2O_2 , NO_2^- , O_3^- or short-lived species has been extensively described¹⁻⁴. The plasma-treated or plasma-conditioned liquids (PCL) with biological effects provide a new window of opportunities for local treatment by injecting in the disease site. Taking advantage of the different basal levels of oxidative stress between healthy and cancer cell lines⁵⁻⁸, and the different sensitivity to reactive oxygen species (ROS), previous works demonstrated the selective effects of PCL on killing cancer cells⁹⁻¹⁵. However, injection of PCL to the tumor may quickly be washed away by body fluids, so design of suitable biomaterials for delivery of these oxidative stress is of paramount importance. In this sense, and to also foster higher concentrations of RONS in suitable biocompatible vehicles studies on PCL were broadened to alginate solutions, that proved to be good candidates to enhance generation of RONS¹⁶. Therefore, developing vehicles of these RONS for enhanced local delivery to the diseased site would be a very interesting asset.

Gelatin is a translucent and thermosensitive hydrogel derived from collagen. Since collagen is the most abundant extracellular matrix protein in humans and animals, and the main component of connective tissues (such as skin, ligament, tendons, etc.), gelatin presents a high biocompatibility, making it a great candidate to be used in the design of hydrogel-based implantable biomaterials. Indeed, as biomaterials for tissue engineering, a wide diversity of gelatin-based structures have been described in literature¹⁷ including nano- and microspheres^{18,19} or particles, 3D scaffolds²⁰⁻²⁴, electrospun nanofibers²⁵⁻²⁷, cryogel scaffolds²⁸, composite materials²⁹⁻³¹ and *in situ* gelling formulations. This reverts in a broad range of applications going from drug and growth factors delivery^{18,19,30} to tissue repair and regeneration for ocular²³, bone³⁰, skeletal muscle³² or soft tissue^{24,31} engineering.

The first studies involving cold atmospheric plasma treatment of gelled gelatin used it as a surrogate of human tissues – i.e. skin - to study its barrier effects on incoming RONS generated by different kinds of plasma treatment (plasma jet, barrier discharge). The penetration of RONS through gelatin gel films was quantified measuring the concentrations in the water underneath such films³³⁻³⁵. Other materials such as agarose³⁶ and phospholipid membranes³⁷ were employed to model living tissues, where the authors also focused on the transport and diffusion of the RONS through these layers.

Here, we intend to describe for the first time the ability of gelatin solutions to successfully increase, store and deliver reactive species generated by cold atmospheric plasmas with the purpose to further include the plasma-treated biopolymer in the design of hydrogel-based biomaterial acting as vehicles of RONS for cancer therapy. A wide variety of plasma jets have been described, producing different biological effects, so here focus will be put on comparing a helium atmospheric pressure plasma jet (APPJ) to a standard commercial source argon jet (known as kINPen) on the production of RONS in gelatin and investigating its potential biological effects.

2. EXPERIMENTAL SECTION

2.1. Materials

Gelatin type B (Rousselot 250 LB8, Rousselot, France), in powder form and MilliQ water (MilliPore, Merck) (designated here as DI water) were used for preparation of biopolymer solution. Argon (Ar 5.0) and Helium (He 5.0) employed as precursor gas to generate plasma (PRAXAIR, Spain).

Sulfanilamide (Sigma-Aldrich, USA), N-(1-naphthyl)ethylenediamine dihydrochloride (Sigma-Aldrich, USA) and ortho-phosphoric acid 85%, pure, pharma grade (H_3PO_4) (85%) (Panreac, USA) have been used for the preparation of Griess reagent, used for NO_2^- detection. Sodium nitrite (NaNO_2 , Sigma-Aldrich, USA) used for calibration curves of nitrites. Sodium azide (NaN_3), Titanium(IV) oxysulfate-sulfuric acid solution (TiOSO_4) and 30% (w/w) hydrogen peroxide (H_2O_2) solution used for detection of hydrogen peroxides in water were purchased from Sigma Aldrich. AmplexTMRed reagent (InvitrogenTM, Thermo Fisher Scientific) and peroxidase from horseradish (Type VI) (HRP) (Sigma-Aldrich, USA) were used for determination of H_2O_2 in gelatin.

NunclonTM Delta Surface 24-well and 96-well plates (ThermoFisher Scientific) and Corning[®] Transwell[®] polyester membrane cell culture inserts 6.5 mm Transwell[®] with 0.4 μm pore polyester membrane insert, TC-treated, sterile (Corning, Inc., USA) were used for *in vitro* cell experiments. Sarcoma osteogenic SaOS-2 (HTB-85, #70014245, ATCC, USA) were cultured in Mc Coy's 5A medium (modified, with sodium bicarbonate, without L-glutamine, liquid, sterile-filtered, suitable for cell culture), purchased from Sigma Aldrich. Bone marrow-derived Mesenchymal Stem Cells hMSC (PCS-500-012, #70014245, ATCC, USA) were cultured in Advanced Dulbecco's Eagle Medium (1X) (AdvDMEM) (Gibco, ThermoFisher Scientific). To supplement cell culture media, Foetal Bovine Serum (FBS), Penicillin/Streptomycin (P/S) and Trypsin were purchased from ThermoFisher Scientific. Dulbecco's Phosphate Buffered Saline (PBS) used for *in vitro* cell assay and release experiments were obtained from Biowest (Biowest SAS, France). For sample preparation for confocal microscopy, Tween 20 (Sigma-Aldrich), SuperBlockTM (TBS) (ThermoScientific, Ref. 37535, USA) Alexa Fluor[®] 546 Phalloidin (InvitrogenTM), ProLong[®] Gold antifade with DAPI (InvitrogenTM, P36931, USA) were used.

2.2. Preparation of gelatin solution

Gelatin in powder form was mixed with MilliQ water at 37 °C using magnetic stirring for 2 hours to obtain a 2% _{wt/wt} gelatin solution. 2% gelatin solution was stored at 4 °C and brought to 37 °C before plasma treatment.

2.3. Plasma treatment

In his work, two plasma sources were employed: an APPJ, using helium as plasma gas and whose design is based on a single electrode as described in literature³⁸ and a commercial kINPen[®] IND (NEOPLAS Tools, Germany)³⁹ operating with argon. Plasma treatment times up to 5 minutes were performed to either water or gelatin solutions. Nozzle distance to the solution surface was tested from 10 mm to 20 mm. Gas flow, controlled by Ar and He Bronkhorst Mass View flow controllers (Bronkhorst[®], Netherlands), was employed between 1 and 5 L/min for APPJ and 1 and 2.5 L/min for kINPen due to the different configurations of the two plasma jets. To evaluate

1
2
3 the effects of APPJ and kINPen plasma treatment conditions on the amount of RONS generated
4 in gelatin solution and the ageing of RONS, 200 μ L of 2% gelatin solution previously warmed at
5 37 °C were put for treatment in a 96-well plate on a dielectric plate at floating potential **Error!**
6 **Reference source not found.**(ungrounded samples). MilliQ water has been used as control in
7 the same conditions.
8
9

10 11 2.4. pH monitoring

12
13 2 mL of 2 % gelatin solution brought to 37 °C were put in 24-well plates and treated with APPJ
14 or kINPen at 10 mm nozzle distance and 1 L/min gas flow. Evolution of the pH as a function of
15 plasma treatment time was measured by using a PC80 Multiparameter instrument
16 (XS Instruments, Italy) with a Crison 50 14 electrode (Crison, Spain).
17
18
19

20 21 2.5. Infrared imaging of plasma-treated gelatin solution

22
23 Non-invasive temperature measurements were effectuated by means of an infrared camera
24 (Fluke Ti480 by Fluke) with resolution of 640x640 pixels and an accuracy of ± 2 °C. An initial
25 calibration of the camera acquisition was effectuated using a standard thermocouple to
26 measure the target temperature by contact. The emissivity was corrected with the calibration
27 procedure. The camera was mounted 15 cm above the sample and focused on the sample
28 surface. The acquisitions are reported on a scale from 10 to 40 °C so to accentuate the
29 temperature gradients.
30
31

32 33 2.6. Detection of RONS

34
35 Quantification of plasma generated NO_2^- in 2% of gelatin solutions and in DI water was
36 performed by Griess test^{1,4,40,41}. Griess reagent (GR) was prepared by dissolution of 0.1 % wt/v of
37 N-(1-naphthyl) ethylenediamine dihydrochloride, 1 % wt/v of sulphanilamide, and 5 % wt/v of
38 phosphoric acid in DI water. 200 μ L of GR were added on the 200 μ L of plasma-treated sample
39 in a 96-well plate (Figure 2a). Incubation of the plate protected from light was done for 10 min
40 at room temperature before absorbance measurement at $\lambda = 540$ nm using a Synergy HTX Hybrid
41 Multi Mode Microplate Reader (BioTek Instruments, Inc., USA). Calibration curves to correlate
42 absorbance with concentration were made from NaNO_2 standard solutions with proper
43 dilutions.
44
45

46
47 Quantification of plasma generated H_2O_2 in 2% gelatin solution or in water was performed by
48 fluorescence measurement from the conversion of H_2O_2 in resorufin (fluorescent product) using
49 100 μ M Amplex™Red reagent with 0.25 U/mL HRP as catalyst. The plasma-treated 2% gelatin
50 solution samples were diluted 1:200 to proceed to the detection of H_2O_2 within the linear
51 concentration range. 50 μ L of the reagent were added to 200 μ L of the diluted samples in a 96-
52 well plate and that was incubated at 37 °C for 30 min. Fluorescence measurements were
53 performed using a Synergy™ HTX Multi-Mode Microplate Reader (Biotek, USA) using 560/20 nm
54 and 590/20 nm as filters for excitation and emission wavelengths, respectively.
55
56
57
58
59
60

2.7. Stability of RONS

The time stability of H_2O_2 and NO_2^- after storage of the plasma-treated 2% gelatin solution was measured following the protocol previously described, for each of the species. Gelatin solutions was stored either at 4 °C or 37 °C. DI water was used as control.

2.8. Release of RONS from plasma-treated hydrogels

200 μL of 2% gelatin solution were treated by APPJ or kINPen in 96-well plate at 10 mm with gas flow rate of 1 L/min during 30, 90 and 180 s. Then, plasma-treated gelatin samples, together with untreated gelatin as control, were transferred into Corning® Transwell® cell culture inserts and placed in 1 mL of PBS used as release medium in 24-well plates. Release kinetics of RONS from the gelatin to the PBS were plotted from withdrawals of 100 μL of the release medium at determined time points. 50 μL were used for NO_2^- and 50 μL for H_2O_2 detection, following the same experimental protocol described for RONS detection in DI water. 100 μL of fresh PBS at 37 °C were replaced after each sample withdrawal. At the end of the release experiments, final volumes of the release media were measured to consider any water evaporation. Thus, two volume corrections were taken into account to determine precisely the concentration RONS in the release medium at each moment t : (i) a step to step correction due to sample withdrawal and (ii) a total volume correction due to evaporation. Gelatine solutions were treated by plasma immediately before starting the RONS release experiments (without any storage time).

2.9. *In vitro* cell experiments

Sarcoma osteogenic SaOS-2 cells were used to evaluate the cytotoxicity of the plasma-treated 2% gelatin solutions on cancer cells. Cell culture medium of SaOS-2 consisted of Mc Coy's 5A medium supplemented with 10% FBS and 1% P/S. Subconfluent SaOS-2 were detached from the flask using trypsin, centrifuged and seeded with a density of 10000 cells/well in 24-well plates with 1 mL volume of complete cell culture medium. After 6-hour adhesion, plasma-treated 2% gelatin solution samples were transferred to Transwell® inserts and placed in the wells. Gelatin solution used for cell experiments was previously heated at 37 °C and filtered with 0.22 μm -diameter pore Millex-GP filters (Millipore, Merck) before plasma treatment. Plasma treatments of the 2% gelatin solution used for *in vitro* cell experiments were performed with APPJ or kINPen for 30, 90 and 180 s using a 10 mm nozzle distance and 1 L/min gas flow rate. The same density of cells was seeded in the same conditions in empty well (cell only) and in presence of untreated gelatin, as controls. The cells were grown at 37 °C for another 24 and 72 hours.

Bone marrow-derived Mesenchymal Stem Cells (hMSC) were used to evaluate the selectivity of plasma-treated gelatin between cancer and healthy cell lines. Cell culture medium of hMSC consisted of AdvDMEM supplemented with 10% FBS and 1% P/S. Seeding, cell density and experimental design of hMSC were reproduced in the exact same conditions such as presented above with SaOS-2. hMSC cell viability was evaluated at 72 hours for cells in presence of untreated gelatin (control), APPJ- or kINPen-treated 2% gelatin solutions for the longest plasma treatment studied (180 s).

1
2
3 Cell viability at 24 and 72 hours was evaluated with WST-1 reagent following supplier's protocol.
4 Absorbance was measured at $\lambda_{\text{abs}} = 440$ nm using a Synergy HTX Hybrid Multi Mode Microplate
5 Reader (BioTek Instruments, Inc., USA). Normalization of the absorbance values was made with
6 respect to cells only to determine the effects of untreated and plasma-treated 2% gelatin
7 solution on SaOS-2 cell viability. Cell viability was also assessed by imaging the well plates by
8 optical microscopy to check the coherence of the results.
9
10

11 12 13 2.10. Confocal Laser Scanning Microscopy

14
15 SaOS-2 cells were seeded on round glass slides in the bottom of a 24-well plate with a density
16 of 3.0×10^4 cells per well in 1 mL of McCoy's 5A medium supplemented with 10% FBS and 1% P/S.
17 After 6-hour adhesion, plasma-treated gelatin samples were transferred to Transwell® inserts
18 and placed in the wells. The same density of cells was seeded in the same conditions without
19 adding gelatin, as positive control. After 48 hours, SaOS-2 cells were fixed with 4%
20 paraformaldehyde (PFA)/DPBS for 30 min at room temperature, 3x washed with PBS, and
21 permeabilized with 0.1% Tween20/PBS during 30 min. They were washed three times with PBS
22 and non-specifically points were blocked using SuperBlock™ (TBS) for 2 h. Then, cells were 3x
23 washed and actin filaments were labelled using Alexa Fluor® 546 Phalloidin (AF546)/PBS in a
24 dilution 1:300 to discern the cytoskeleton. After 1-hour incubation, samples were washed three
25 times with PBS, and mounted using ProLong® Gold antifade with DAPI, allowing nuclei staining.
26 SaOS-2 cells were imaged with a Zeiss LSM 800 Confocal Laser Scanning Microscope (CLSM) and
27 processed with ZEN 2.3 software (Zeiss, Germany). Immunofluorescence images were taken
28 using a 40x oil objective, using 557 nm and 353 nm as excitation wavelengths and 560-700 nm
29 and 400-555 nm as detection wavelengths for AF546 and DAPI, respectively.
30
31
32
33
34

35 2.11. Data analysis

36
37
38
39 Statistical differences were determined using one-way ANOVA a 95% confidence with Tukey's
40 post-tests using Minitab 19 software (Minitab, Inc., State College, PA). Statistical significance
41 was noted when $p < 0.05$.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3. RESULTS

3.1. Thermal effects of cold atmospheric plasma treatment




Figure 1: Configuration of the plasma treatment of gelatin using an APPJ and kINPen (a) together with the physical aspect of gelatin as function of temperature (inset). Thermal effects after 180 s of plasma treatment of water or 2% gelatin solution using APPJ and kINPen (10 mm, 1 L/min) monitored by infrared camera. The temperature value is calculated as an average over the gelatine surface (b).

Plasma treatments of 200 μL gelatin solution and water have been performed using APPJ and kINPen. The temperature of the solution was measured by IR imaging before and after plasma treatment and comparative results are presented in Figure 1. While both water and gelatin remain around the initial temperature after 180 s plasma treatment for kINPen device, plasma treatment using APPJ induces cooling for both samples, with a decrease of 11 °C and 12 °C for gelatin and water, respectively. To study the contributions of the gas flow on the thermal effects caused on water and gelatin, controls with only gas flow were performed (Supplementary Figure 1). Both devices are fed with high purity dry gas (Ar or He) which induces strong evaporation from the gelatin/water free surface. The thermal energy lost to evaporation induces a cooling of the sample as confirmed by only gas tests. Assuming the enthalpy of water vaporization in gelatin solution is the same as in pure water (2257 J/g), an evaporation of 100 μL over 180 s

1
2
3 results in a cooling power of approximately 1.25 W. On the other side, a portion of the total
4 power consumed by the plasma sources (2.1 W for APPJ and 8.4 W for kINPen on the gelatin
5 solution) is delivered to the target as heat through Joule effect or electromagnetic emission.
6 While for APPJ the cooling effect is stronger than the heating one, for kINPen they are
7 comparable. Both plasma devices warm the samples, but in the case of kINPen, the warming
8 effect is sufficient to counterbalance the cooling effect of evaporation. This can be attributed to
9 the different powers of the two sources.
10
11
12
13

14 3.2. Influence of plasma treatment on the generation of RONS in gelatin

15
16 Figure 2b & c show the concentration of NO_2^- and H_2O_2 generated in 2% gelatin solution or
17 distilled water as a function of the plasma treatment time, using APPJ or kINPen. Higher amount
18 of NO_2^- and H_2O_2 was measured in 2% gelatin solution compared with water for any of the
19 conditions studied. In both cases of hydrogel or water, production of RONS increases with the
20 plasma treatment time. In DI water, NO_2^- concentration does not further increase after 2-min
21 plasma treatment. Furthermore, production of RONS by kINPen is always higher than using APPJ
22 in 2% gelatin solution and it is equal or higher for water, for similar plasma treatment times.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Plasma treatment of distilled water and 2% gelatin solution in presence of Griess reagent for NO₂⁻ detection (a). Influence of plasma treatment time on NO₂⁻ (b) and H₂O₂ (c) generation in APPJ- (i) and kINPen-treated (ii) 2% gelatin solution for 10 mm nozzle distance to the liquid surface and 1 L/min gas flow rate, together with the controls in DI water. Monitoring of the pH of 2% gelatin and DI water in the same conditions (d).

The pH of water decreases quickly at short plasma treatment times to below 3 after 900 s of treatment, while the pH of 2% gelatin solution remains between 5.5 and 6 up to 900 s (Figure 2d), highlighting a pH buffering effect of the gelatin.




Figure 3. Influence of plasma gas flow rate distance on the concentration of NO_2^- (a) and H_2O_2 (b) from APPJ- and kINPen-treated 2% gelatin for 90 s. Different letters indicate statistically significant differences (mean sd, $n=3$; $p<0.05$).

Gas flow rate and distance from the nozzle to the surface of the liquid also play a significant role in the concentration of RONS generated in gelatin (Figure 3a) clearly indicates that higher concentrations of NO_2^- are generated in gelatin solution under low gas flow rate and short nozzle distance. $[\text{NO}_2^-]$ is maximized for both plasma devices at 1 L/min of gas flow rate and 10 mm nozzle distance, with concentrations of 112 μM and 219 μM for APPJ and kINPen, respectively. Under the same working conditions, kINPen generates much more nitrites than APPJ for all conditions studied. In contrast, production of H_2O_2 in gelatin (Figure 3b) does not follow the same trend with APPJ with the variation of both nozzle distance and gas flow rates. kINPen displays an increase of H_2O_2 production with the decrease of the nozzle distance, as observed for NO_2^- . In parallel, variation of gas flow does not display variation in the generation of hydrogen peroxides in kINPen-treated gelatin at 15–20 mm but increases at short distance when increasing gas flow rate.

3.3. Stability of RONS in gelatin-based hydrogel

To study the stability of RONS generated in 2% gelatin solution NO_2^- and H_2O_2 were quantified at different times after plasma treatment, at two storage temperatures: 4 °C and 37 °C and compared to DI water as control (Figure 4).




Figure 4: Influence of the storage time and temperature on the ratio of RONS remaining with respect to the initial concentrations of NO_2^- (a) and H_2O_2 (b) in 2% gelatin and water generated by APPJ (left side) and kINPen (right side) plasma treatment (10 mm, 1 L/min, 90 s).

For both APPJ- and kINPen-treated water, a quick decrease of nitrites is observed as a function of the storage time, with a quicker disappearance of NO_2^- at 37 °C than at 4 °C. No nitrite ions were detected in water after 24h. This NO_2^- decreasing trend is slowed down in plasma-treated gelatin, wherein after 24 hours, around 90% and 55% of the initial concentration of NO_2^- remains in the biomaterial (for APPJ and kINPen, respectively). While almost all NO_2^- ions react within the first 24 hours in plasma-treated water, hydrogen peroxides are stable, even after hours. The same stability is observed in plasma-treated 2% gelatin solution, in which H_2O_2 concentration remains constant over 72-hour storage either at 4 °C or 37 °C. To sum up, gelatin hydrogels improve the stability of plasma-generated RONS, as they allow maintaining constant concentration of NO_2^- and H_2O_2 over time.

3.4. Release studies of RONS from plasma-treated hydrogels

The release of NO_2^- and H_2O_2 from the plasma-treated 2% gelatin to PBS (Figure 5) shows a clear dependence of plasma treatment time. Higher release of NO_2^- and H_2O_2 was recorded for longer treatment times, according to the higher initial amount of RONS in the biopolymer. Similarly, the higher amount of RONS generated with kINPen (Figure 2 and Figure 3) result in higher concentrations of nitrites and peroxides released than from the APPJ-treated gelatin solution.





Figure 5. RONS released from APPJ- and kINPen-treated 2% gelatin solution for 30, 90 and 180 s plasma treatment (10 mm, 1 L/min) to PBS release medium: concentration of NO_2^- (a) and H_2O_2 (b). Untreated gelatin solution was employed as control.

3.5. *In vitro* anticancer efficacy

Sarcoma osteogenic SaOS-2 cells were exposed to APPJ- and kINPen-treated 2% gelatin to evaluate the impact on cell viability (Figure 6a). As expected, untreated gelatin is completely biocompatible. The plasma-treated gelatin induced bone cancer cell death, with SaOS-2 cell viability decrease by increasing of treatment time, for both plasma devices tested, but being treatment with kINPen more effective on suppressing viability of osteosarcoma cells. Short plasma treatment times (30 s) already reveal important cytotoxic effects on SaOS-2 cells, with cell viability of 71% for APPJ and 57% for kINPen after 24 hours. Cell viability diminished to 46% and 27% after 24 hours for 180 s APPJ and kINPen treatment, respectively, and further decreased to 23% and 12% after 72 hours. Additionally, while SaOS-2 cells grow homogeneously in the well plate when using untreated gelatin, SaOS-2 are killed preferentially just below the insert with the treated gelatin (lack of cells in this area). The diameter of this area of arrested proliferation increases with plasma treatment time, with absence of living cells for longer plasma treatment times in this area (Supplementary Figure 2). It can be assumed that this corresponds to the area of diffusion of RONS nearer the plasma-treated gelatin solution, confirming that the release of RONS is closely linked with the biological effects observed.



46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 6. SaOS-2 cell viability after 24 h and 72 h exposition to APPJ and kINPen (K)-treated 2% gelatin for 30, 90 and 180 s (a). Selectivity of plasma-treated gelatin for 180 s using APPJ and kINPen (10 mm, 1 L/min) (b). Different letters indicate statistically significant differences (mean sd, n=3; p<0.05). Confocal microscopy images of SaOS-2 cells placed for 48 hours in presence of untreated gelatin (control) and APPJ-treated gelatin for 90 s at 1 L/min and 10 mm (c).

Confocal microscopy images (Figure 6b) confirm the previous results; SaOS-2 cells in presence of untreated gelatin display the same morphology than control with cells only. APPJ-treated gelatin induces morphological modifications reflected by a reduction of the expansion or an absence of actin filaments and a reduction of the nuclei size.

Finally, the selectivity of the plasma-treated biomaterial was also tested with hMSC in presence of APPJ and kINPen-treated 2% gelatin solution for 180 seconds as presented in Figure 6c. While

1
2
3 presence of untreated gelatin solution with hMSC confirms the biocompatible behavior of the
4 material with 72-hour cell viability around 91%, the results revealed that plasma treatments of
5 gelatin in the studied conditions have selective effects on cancer cells, maintaining cell viability
6 of healthy cells of $91.9 \pm 3.4\%$ and $86.8 \pm 4.5\%$ for 180 s APPJ and kINPen treatment, respectively.
7
8
9

10 4. DISCUSSION

11
12 Many studies have shown proof of the anticancer efficacy of plasma-conditioned liquids (PCL)
13 such as physiological saline solutions or culture media^{9,10,12,14,42-45}. As alternative to direct
14 treatment of cancer cells by CAP^{46,47}, that could results more aggressive for healthy cells, the use
15 of PCL presents the advantage of being a minimally-invasive approach with similar *in vitro*
16 results, including better outcomes especially regarding selectivity. However, one of their
17 limitations is that while they can be delivered locally, the liquids can be quickly washed away by
18 body fluids. Here, the production of RONS by plasma jets was enhanced by using a polymer
19 solution of gelatin (Figure 2) with respect to other saline solutions⁴⁵ or to the first work
20 evaluating a biopolymer solution of alginate¹⁶. This opens the door to entrapping these RONS in
21 a biopolymer formulation able to act as vehicle for local delivery of RONS for cancer therapy,
22 potentially allowing extended local therapy with the RONS in the tumor site (Figure 4) rather
23 than the conventional plasma-conditioned saline solutions.
24
25
26

27 Gelatin has been widely used as carrier material for therapeutic cells and drugs due to their
28 excellent biocompatibility and similarities to the extracellular matrix⁴⁸. To meet the stringent
29 requirements of clinical translation of the hydrogels such preparation, application, mechanical
30 properties, etc. a number of modifications of gelatin have also been investigated⁴⁹.
31
32

33 Until now, some works have investigated the diffusion of RONS from plasma jets through gelled
34 (solid) gelatin^{34,35,50} and agarose^{36,51-54}, used as tissue models in plasma medicine. These studies
35 showed that plasma treatment of mm thick gelled gelatin or agarose allow the diffusion of
36 reactive species to a liquid below, as it is thought to happen *in vivo*, with RONS going through
37 the skin.
38

39 Our approach here is novel, as we treat liquid gelatin solutions with cold atmospheric plasma
40 jets to generate RONS within it with the aim to include afterward the plasma-treated biopolymer
41 in the design/formulation of a biomaterial able to act as a delivery system.
42
43

44 Different works⁵⁵ have investigated the production of RONS in water or saline solutions under a
45 broad range of conditions such as volume, treatment time, gas flow and electrode
46 distance^{2,45,51,56-58}. To allow easier extrapolation of results, two plasma jets were employed here.
47 Despite that the great variety of configurations in the plasma literature hamper comparative
48 analysis, it is clear that employing a gelatin solution here leads to much higher generation of
49 RONS. Plasma treatment of the 2% gelatin solution allowed obtaining high concentrations of
50 nitrites and peroxides (Figure 2 & 3). In water (used as control), the concentrations of NO_2^- and
51 H_2O_2 generated agree with those observed in plasma-conditioned water in previous works^{55,56}
52 using an APPJ in very similar conditions (20 mm, 100 μL) to those employed here. As in our work,
53 the amount of RONS generated increases with plasma treatment time.
54
55

56 Nevertheless, compared to DI water, the amount of RONS generated in 2% gelatin solution is
57 much higher with any of the two plasma jets investigated here (APPJ or kINPen) (Figure 2). After
58 3 min of plasma treatment, the amounts of NO_2^- and H_2O_2 generated in gelatin are at least 2
59
60

1
2
3 times higher than in water and can reach up to 4.1 and 7.4 fold for NO_2^- with APPJ and kINPen,
4 respectively. This enhanced production of RONS in a biopolymer solution than in water or
5 Ringer's saline was also observed in our previous work with alginate solutions⁵⁹. This difference
6 can be explained by the pH buffering effect of the gelatin solution; while pH decreased with
7 plasma treatment time in Ringer's saline⁵⁹ or water (Figure 2d), as also reported in other works⁶⁰⁻
8 ⁶², the pH remained unaltered in buffered saline such as PBS, in alginate⁵⁹ or here in gelatin
9 solution. In general, different reactions are fostered in acidic media: NO_2^- reacts with H_2O_2 to
10 form peroxyntrites; nitrous acid – one of the major sources of nitrites - decomposes in acidic
11 media^{4,55,63,64}, among other reactions. Since plasma treatment leads to water acidification,
12 these reactions are promoted in water. However, as gelatin solutions are not displaying
13 acidification (Figure 2d) the reactions consuming peroxides and nitrites are slowed down,
14 leading to higher stability of these RONS. While this hypothesis is clearly a common trend
15 between plasma-treated gelatin solution and plasma-treated alginate solution⁵⁹, the present
16 work demonstrates that the specific polymer employed to produce the solution is also a
17 keypoint regarding the chemical reactivity of the solution with the plasma gas phase. Gelatin
18 solutions are able to generate several-fold higher concentrations of RONS than alginate
19 solutions (i.e. 226.4 μM of NO_2^- and 740 μM of H_2O_2 were generated in gelatin solution vs. 97.2
20 μM of NO_2^- and 111.9 μM of H_2O_2 , in alginate solution under same conditions - 90 s of kINPen
21 treatment in 200 μL of solution at 10 mm distance and 1 L/min Ar flow rate).

22
23
24
25
26
27 Parameters such as plasma gas flow rate or nozzle distance to the liquid surface can be modified
28 to obtain maximum NO_2^- and H_2O_2 concentrations in the liquids treated. Here we observed that
29 NO_2^- are maximized at short nozzle distance and low gas flow rate, while short distances and
30 high gas flow rates promote higher concentrations of H_2O_2 (Figure 3). As recorded in a previous
31 work, production of RONS is more efficient under same treatment conditions using kINPen than
32 APPJ⁵⁹ (Figure 2 and Figure 3). One of the reasons supporting this difference between both
33 devices could lie with the thermal effects observed in Figure 1b that can affect fluid dynamics
34 and thus generation of RONS. While plasma treatment using kINPen is maintaining the
35 temperature of the polymer solution or the water during plasma-treatment for a same gas flow
36 rate and nozzle distance, the cooling down observed with the samples treated with APPJ may
37 affect the diffusion of the reactive species inside the plasma-treated polymer solution due to its
38 higher viscosity, as gelatin starts jellying at temperatures from 25-28 °C depending on the
39 concentration and the length of the chain, among others⁶⁵. Lower temperatures revert in a
40 material tending to get a more solid-like behavior, limiting thus the diffusion and generation of
41 RONS inside the polymer network. The difference of behavior in the thermal effects of the
42 samples between APPJ and kINPen most likely arise from the difference of power delivered by
43 both plasma sources. Since the water content in the gas flow is zero in both cases, and thus the
44 contribution of the cooling effect due to evaporation is the same, it can be assumed that the
45 higher power delivered to the plasma discharge by the kINPen (between 0.3 and 3.5 W⁶⁶) with
46 respect to the power delivered by the APPJ (0.3 W measured) is the main reason of the higher
47 counterbalancing in the warming effect presented by the kINPen.

48
49
50
51
52
53 Another important difference between the two sources comes from the type of gas used (He for
54 the APPJ and Ar for the kINPen). Assuming a kinematic viscosity of $1.11 \times 10^{-4} \text{ m}^2/\text{s}$ for He and of
55 $1.27 \times 10^{-5} \text{ m}^2/\text{s}$ for Ar, for the gas flow rates (1-5 L/min) and the nozzle diameters (APPJ \varnothing 1.2
56 mm, kINPen \varnothing 1.6 mm) adopted in this work the Reynolds number (Re) ranges between 158 and
57 792 for the APPJ in He and between 1042 and 5200 for the kINPen in Ar. As reported in the
58 literature for a similar jet configuration, a transition from laminar to turbulent flow is expected
59 to occur for Re between 500 and 1000. Thus, it can be assumed that the APPJ operates mostly
60

1
2
3 in a laminar flow regime while the kINPen in a turbulent one. The turbulent vortexes in the
4 kINPen effluent, while limiting the length of the plasma plume (see in Figure 3 the rapid decrease
5 of RONS with increase of the gap distance), can certainly favor the mixing with surrounding air
6 and therefore allow higher production of RONS with respect to the APPJ^{67,68}.

7
8
9 Furthermore, the buffering effect observed here in gelatin solution (Figure 2b (i and ii)) may also
10 have two important implications: 1. Cancer cells are known to acidify their environment and,
11 consequently, the interior of the cells themselves is alkalinized. This reverse pH gradient is
12 associated with tumor proliferation, invasion, metastasis, aggressiveness, and treatment
13 resistance⁶⁹⁻⁷⁵, so the fact of having a buffered delivery vehicle for the plasma-generated RONS
14 (instead of the acidic plasma-treated liquids proposed earlier) might be an advantage which
15 should deserve investigation in future works. 2. A more practical advantage of this pH buffering
16 of gelatin is that it allows the use of the Amplex Red method for detection of H₂O₂, since the
17 HRP enzyme employed in this method remains stable in a pH range between 5.0 and 9.0.

18
19
20 In designing biomaterials, the ability to store them is a practical and important asset in views of
21 future commercialization. Interestingly, storage of plasma-treated DI water and gelatin at 4 °C
22 or physiological conditions (37 °C) revealed that NO₂⁻ is more stable in the gelatin solution with
23 respect to water (Figure 4). Whereas almost all the nitrites generated in water disappeared after
24 24 hours, at least 60% of the initial concentration of nitrites generated in 2% gelatin remained
25 in the material after 72 hours. Meanwhile, H₂O₂ presents a good stability over time up to 72
26 hours, either for water or gelatin solution, with at least 84.9% of the initial concentration of
27 hydrogen peroxides remaining in gelatin solution after 3-day storage. This trend is not only in
28 accordance with a previous work monitoring storage of H₂O₂ in water over 21 days⁶⁰, but above
29 all it highlights a better conservation of H₂O₂ in water or gelatin than observed in cell culture
30 media, such as DMEM⁷⁶, where H₂O₂ concentrations reported were 10 times lower after 24
31 hours.

32
33
34
35 Release kinetics of NO₂⁻ and H₂O₂ from APPJ- and kINPen-treated gelatin solution to PBS, clearly
36 show that higher amounts of RONS were released from treated gelatin solution for longer
37 treatment times (Figure 5). A sustained release of NO₂⁻ can be observed up to 48 hours, whereas
38 H₂O₂ shows burst release, with maximum released after 4-6 hours. While 180 s plasma-treated
39 gelatin solution releases 75% of NO₂⁻ generated with APPJ and 67% with kINPen after 72 hours,
40 the release percentage of H₂O₂ to PBS is much lower, with values of 7% and 15%, respectively
41 (Supplementary Table 1). However, despite the low release percentage of hydrogen peroxides,
42 the concentrations released allow to observe significant biological effects of SaOS-2 cells (Figure
43 5).

44
45
46
47 Osteosarcoma (SaOS-2) cell death was enhanced progressively with plasma-treated gelatin at
48 increasing treatment times (Figure 6a). This can be related to the increasingly higher
49 concentration of RONS produced by plasma jet (Figure 7). This death of cancer cells in a dose-
50 dependent manner has been previously associated with biological and molecular mechanisms
51 of necrosis, apoptosis, senescence, and autophagy triggered by CAP treatment⁷⁷. With [H₂O₂]
52 around 200 μM after 30 s of plasma treatment, cytotoxic effects are already observed with the
53 shortest plasma treatment time. Slightly higher cell cytotoxicity with kINPen than with APPJ can
54 be directly related with the higher amount of RONS generated in the gelatin solution with this
55 plasma jet (Figure 2 and Figure 3). By producing higher amounts of RONS in gelatin than in
56 alginate solutions under the same plasma treatment conditions¹⁶, an important enhancement
57 of cancer cell cytotoxicity is reached by using gelatin solutions, with 72-hour cell viability
58 decreasing down to 12% by using kINPen for 180 s when alginate solutions presented a SaOS-2
59
60

cell viability of 62% for the same CAP treatment conditions. This supports to employ preferentially gelatin as biopolymer solution in a further design of CAP-treated biopolymer-based biomaterial to obtained higher loading of RONS and thus, an improve effectiveness in killing cancer cells.




Figure 7: Relationship between NO₂⁻ (a) and H₂O₂ (b) generated in 2% gelatin solutions and the cytotoxicity observed in SaOS-2 cell viability after 24 hours for APPJ and kINPen treatments (10 mm, 1 L/min).

Morphology and cell density imaged by confocal microscopy (Figure 6b) backup the discussed cellular results for gelatin solution. SaOS-2 osteosarcoma cells in presence of either untreated hydrogels present extended actin filaments and high cell density, accordingly to their suitable biocompatibility (Figure 5a). On the contrary, osteosarcoma cells cultured with plasma-treated gelatin show isolated cells, with fewer adhesion points, smaller nuclei size and more rounded shape, all indicative of the dying fate induced by the plasma-treated biopolymer solutions developed here. Finally, and most importantly, plasma-treated gelatin revealed a selective killing effect on osteosarcoma cells since cell viability of healthy cells (hMSC) is maintained above 90% after 72 hours (Figure 6c). This selective behavior observed with plasma-treated biopolymer solution is in accordance with results obtained in previous works using plasma-conditioned liquids^{15,78,79}. As hypothesized for PCL, the mechanism behind this selectivity mainly takes its origin in the difference in basal levels of oxidative stress between healthy and cancer cells lines^{8,12}. So, plasma treatment of biopolymer solutions discussed here has several advantages regarding generation and stability of RONS, and above all preserve the biological effects observed with PCL.

5. CONCLUSIONS

Herein we designed and characterized a novel vehicle for atmospheric pressure plasma-generated RONS by comparing two different atmospheric pressure plasma jets. Gelatin solution greatly increases (between 2 and 12-fold) the concentration of RONS produced by cold atmospheric plasma with respect to water. The stability of NO₂⁻ generated in gelatin was enhanced and that of H₂O₂ was maintained with respect to DI water at least for 72 h. Plasma-treated gelatin solution buffered the pH decrease observed in water which can be an advantage and partially explains the higher RONS measured. Anticancer effects of plasma-treated gelatin solution are time-dependent in SaOS-2 osteosarcoma cells, being closely related with the increase of RONS generated by plasma at longer treatment times that reverts in a higher release

of RONS. Plasma-treated gelatin solution revealed a selective lethality on osteosarcoma cells since cell viability of healthy hMSC cells is maintained above 86% after 72 hours for the longest plasma treatment studied (3 min), while viability of SaOS-2 decreased to 23% and 12% for APPJ and kINPen, respectively. The set of unique features previously described make of gelatin a great candidate for the generation and storage of RONS generated by cold atmospheric plasmas and a relevant material to be used in the design of implantable delivery system, with promising applicability in cancer therapy.

6. ACKNOWLEDGMENTS

This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 714793). Authors acknowledge the financial support of MINECO for MAT2015-65601-R project (MINECO/FEDER, EU), for the RyC fellowship of CC and of Generalitat de Catalunya for the SGR2017-1165. Support for the research of MPG was received through the ICREA Academia Award for excellence in research, funded by the Generalitat de Catalunya.

7. REFERENCES

- (1) Bruggeman, P. J.; Kushner, M. J.; Locke, B. R.; Gardeniers, J. G. E.; Graham, W. G.; Graves, D. B.; Hofman-Caris, R. C. H. M.; Maric, D.; Reid, J. P.; Ceriani, E.; Fernandez Rivas, D.; Foster, J. E.; Garrick, S. C.; Gorbanev, Y.; Hamaguchi, S.; Iza, F.; Jablonowski, H.; Klimova, E.; Kolb, J.; Krcma, F.; Lukes, P.; MacHala, Z.; Marinov, I.; Mariotti, D.; Mededovic Thagard, S.; Minakata, D.; Neyts, E. C.; Pawlat, J.; Petrovic, Z. L.; Pflieger, R.; Reuter, S.; Schram, D. C.; Schröter, S.; Shiraiwa, M.; Tarabová, B.; Tsai, P. A.; Verlet, J. R. R.; Von Woedtke, T.; Wilson, K. R.; Yasui, K.; Zvereva, G. Plasma-Liquid Interactions: A Review and Roadmap. *Plasma Sources Science and Technology*. 2016. <https://doi.org/10.1088/0963-0252/25/5/053002>.
- (2) Chauvin, J.; Judée, F.; Yousfi, M.; Vicendo, P.; Merbahi, N. Analysis of Reactive Oxygen and Nitrogen Species Generated in Three Liquid Media by Low Temperature Helium Plasma Jet. *Sci. Rep.* **2017**. <https://doi.org/10.1038/s41598-017-04650-4>.
- (3) Verlackt, C. C. W.; Van Boxem, W.; Bogaerts, A. Transport and Accumulation of Plasma Generated Species in Aqueous Solution. *Phys. Chem. Chem. Phys.* **2018**, *20* (10), 6845–6859. <https://doi.org/10.1039/C7CP07593F>.
- (4) Machala, Z.; Tarabova, B.; Hensel, K.; Spetlikova, E.; Sikurova, L.; Lukes, P. Formation of ROS and RNS in Water Electro-Sprayed through Transient Spark Discharge in Air and Their Bactericidal Effects. *Plasma Process. Polym.* **2013**. <https://doi.org/10.1002/ppap.201200113>.
- (5) Yilmazer, A. Cancer Cell Lines Involving Cancer Stem Cell Populations Respond to Oxidative Stress. *Biotechnol. reports (Amsterdam, Netherlands)* **2017**, *17*, 24–30. <https://doi.org/10.1016/j.btre.2017.11.004>.
- (6) Reuter, S.; Gupta, S. C.; Chaturvedi, M. M.; Aggarwal, B. B. Oxidative Stress,

- 1
2
3 Inflammation, and Cancer: How Are They Linked? *Free Radic. Biol. Med.* **2010**, *49* (11),
4 1603–1616. <https://doi.org/10.1016/j.freeradbiomed.2010.09.006>.
5
- 6 (7) Schumacker, P. T. Reactive Oxygen Species in Cancer: A Dance with the Devil. *Cancer*
7 *Cell* **2015**, *27* (2), 156–157. <https://doi.org/10.1016/j.ccell.2015.01.007>.
8
- 9 (8) Trachootham, D.; Alexandre, J.; Huang, P. Targeting Cancer Cells by ROS-Mediated
10 Mechanisms: A Radical Therapeutic Approach? *Nat. Rev. Drug Discov.* **2009**, *8*, 579.
11
- 12 (9) Van Boxem, W.; Van Der Paal, J.; Gorbanev, Y.; Vanuytsel, S.; Smits, E.; Dewilde, S.;
13 Bogaerts, A. Anti-Cancer Capacity of Plasma-Treated PBS: Effect of Chemical
14 Composition on Cancer Cell Cytotoxicity. *Sci. Rep.* **2017**.
15 <https://doi.org/10.1038/s41598-017-16758-8>.
16
- 17 (10) Keidar, M. Plasma for Cancer Treatment. *Plasma Sources Sci. Technol.* **2015**, *24* (3),
18 33001.
19
- 20 (11) Keidar, M.; Shashurin, A.; Volotskova, O.; Ann Stepp, M.; Srinivasan, P.; Sandler, A.;
21 Trink, B. Cold Atmospheric Plasma in Cancer Therapy. *Phys. Plasmas* **2013**.
22 <https://doi.org/10.1063/1.4801516>.
23
- 24 (12) Yan, D.; Talbot, A.; Nourmohammadi, N.; Sherman, J. H.; Cheng, X.; Keidar, M. Toward
25 Understanding the Selective Anticancer Capacity of Cold Atmospheric Plasma—A Model
26 Based on Aquaporins (Review). *Biointerphases* **2015**, *10* (4), 40801.
27 <https://doi.org/10.1116/1.4938020>.
28
- 29 (13) Yan, D.; Sherman, J. H.; Keidar, M. Cold Atmospheric Plasma, a Novel Promising Anti-
30 Cancer Treatment Modality. *Oncotarget* **2017**.
31 <https://doi.org/10.18632/oncotarget.13304>.
32
- 33 (14) Tanaka, H.; Nakamura, K.; Mizuno, M.; Ishikawa, K.; Takeda, K.; Kajiyama, H.; Utsumi, F.;
34 Kikkawa, F.; Hori, M. Non-Thermal Atmospheric Pressure Plasma Activates Lactate in
35 Ringer's Solution for Anti-Tumor Effects. *Sci. Rep.* **2016**, *6* (1), 36282.
36 <https://doi.org/10.1038/srep36282>.
37
- 38 (15) Canal, C.; Fontelo, R.; Hamouda, I.; Guillem-Marti, J.; Cvelbar, U.; Ginebra, M. P. Plasma-
39 Induced Selectivity in Bone Cancer Cells Death. *Free Radic. Biol. Med.* **2017**.
40 <https://doi.org/10.1016/j.freeradbiomed.2017.05.023>.
41
- 42 (16) Labay, C.; Hamouda, I.; Tampieri, F.; Ginebra, M.-P.; Canal, C. Production of Reactive
43 Species in Alginate Hydrogels for Cold Atmospheric Plasma-Based Therapies. *Sci. Rep.*
44 **2019**, *9* (1), 16160. <https://doi.org/10.1038/s41598-019-52673-w>.
45
- 46 (17) Echave, M. C.; Saenz del Burgo, L.; Pedraz, J. L.; Orive, G. Gelatin as Biomaterial for
47 Tissue Engineering. *Curr. Pharm. Des.* **2017**, *23* (24), 3567–3584.
48 <https://doi.org/10.2174/0929867324666170511123101>.
49
- 50 (18) Esposito, E.; Cortesi, R.; Nastruzzi, C. Gelatin Microspheres: Influence of Preparation
51 Parameters and Thermal Treatment on Chemo-Physical and Biopharmaceutical
52 Properties. *Biomaterials* **1996**, *17* (20), 2009–2020.
53 [https://doi.org/https://doi.org/10.1016/0142-9612\(95\)00325-8](https://doi.org/https://doi.org/10.1016/0142-9612(95)00325-8).
54
- 55 (19) Solorio, L.; Zwolinski, C.; Lund, A. W.; Farrell, M. J.; Stegemann, J. P. Gelatin
56 Microspheres Crosslinked with Genipin for Local Delivery of Growth Factors. *J. Tissue*
57 *Eng. Regen. Med.* **2010**, *4* (7), 514–523. <https://doi.org/10.1002/term.267>.
58
- 59 (20) Rose, J. C. B. and M. A. and G. E. M. and N. R. W. M. and D. J. P. and A. J. K. and J. W. A.
60

- and M. P. L. and F. R. A. J. Electrospun Gelatin-Based Scaffolds as a Novel 3D Platform to Study the Function of Contractile Smooth Muscle Cells in Vitro. *Biomed. Phys. Eng. Express* **2018**, *4* (4), 45039.
- (21) Poursamar, S. A.; Hatami, J.; Lehner, A. N.; da Silva, C. L.; Ferreira, F. C.; Antunes, A. P. M. Potential Application of Gelatin Scaffolds Prepared through in Situ Gas Foaming in Skin Tissue Engineering. *Int. J. Polym. Mater. Polym. Biomater.* **2016**, *65* (6), 315–322. <https://doi.org/10.1080/00914037.2015.1119688>.
- (22) Tan, J. Y.; Chua, C. K.; Leong, K. F. Indirect Fabrication of Gelatin Scaffolds Using Rapid Prototyping Technology. *Virtual Phys. Prototyp.* **2010**, *5* (1), 45–53. <https://doi.org/10.1080/17452751003759144>.
- (23) Rose, J. B.; Pacelli, S.; Haj, A. J. El; Dua, H. S.; Hopkinson, A.; White, L. J.; Rose, F. R. A. J. Gelatin-Based Materials in Ocular Tissue Engineering. *Mater. (Basel, Switzerland)* **2014**, *7* (4), 3106–3135. <https://doi.org/10.3390/ma7043106>.
- (24) Phull, M. K.; Eydmann, T.; Roxburgh, J.; Sharpe, J. R.; Lawrence-Watt, D. J.; Phillips, G.; Martin, Y. Novel Macro-Microporous Gelatin Scaffold Fabricated by Particulate Leaching for Soft Tissue Reconstruction with Adipose-Derived Stem Cells. *J. Mater. Sci. Mater. Med.* **2013**, *24* (2), 461–467. <https://doi.org/10.1007/s10856-012-4806-0>.
- (25) Aliakbarshirazi, S.; Talebian, A. Electrospun Gelatin Nanofibrous Scaffolds for Cartilage Tissue Engineering. *Mater. Today Proc.* **2017**, *4* (7, Part 1), 7059–7064. <https://doi.org/https://doi.org/10.1016/j.matpr.2017.07.038>.
- (26) Aldana, A. A.; Abraham, G. A. Current Advances in Electrospun Gelatin-Based Scaffolds for Tissue Engineering Applications. *Int. J. Pharm.* **2017**, *523* (2), 441–453. <https://doi.org/10.1016/j.ijpharm.2016.09.044>.
- (27) Dias, J. R.; Baptista-Silva, S.; Oliveira, C. M. T. de; Sousa, A.; Oliveira, A. L.; Bártolo, P. J.; Granja, P. L. In Situ Crosslinked Electrospun Gelatin Nanofibers for Skin Regeneration. *Eur. Polym. J.* **2017**, *95*, 161–173. <https://doi.org/https://doi.org/10.1016/j.eurpolymj.2017.08.015>.
- (28) Fassina, L.; Saino, E.; Visai, L.; Avanzini, M. A.; Cusella De Angelis, M. G.; Benazzo, F.; Van Vlierberghe, S.; Dubruel, P.; Magenes, G. Use of a Gelatin Cryogel as Biomaterial Scaffold in the Differentiation Process of Human Bone Marrow Stromal Cells. *Conf. Proc. ... Annu. Int. Conf. IEEE Eng. Med. Biol. Soc. IEEE Eng. Med. Biol. Soc. Annu. Conf.* **2010**, *2010*, 247–250. <https://doi.org/10.1109/IEMBS.2010.5627475>.
- (29) Zhang, Y.; Ouyang, H.; Lim, C. T.; Ramakrishna, S.; Huang, Z.-M. Electrospinning of Gelatin Fibers and Gelatin/PCL Composite Fibrous Scaffolds. *J. Biomed. Mater. Res. B. Appl. Biomater.* **2005**, *72* (1), 156–165. <https://doi.org/10.1002/jbm.b.30128>.
- (30) Raina, D. B.; Larsson, D.; Mrkonjic, F.; Isaksson, H.; Kumar, A.; Lidgren, L.; Tägil, M. Gelatin- Hydroxyapatite- Calcium Sulphate Based Biomaterial for Long Term Sustained Delivery of Bone Morphogenic Protein-2 and Zoledronic Acid for Increased Bone Formation: In-Vitro and in-Vivo Carrier Properties. *J. Control. Release* **2018**, *272*, 83–96. <https://doi.org/https://doi.org/10.1016/j.jconrel.2018.01.006>.
- (31) Kessler, L.; Gehrke, S.; Winnefeld, M.; Huber, B.; Hoch, E.; Walter, T.; Wyrwa, R.; Schnabelrauch, M.; Schmidt, M.; Kückelhaus, M.; Lehnhardt, M.; Hirsch, T.; Jacobsen, F. Methacrylated Gelatin/Hyaluronan-Based Hydrogels for Soft Tissue Engineering. *J. Tissue Eng.* **2017**, *8*, 2041731417744157–2041731417744157. <https://doi.org/10.1177/2041731417744157>.

- 1
2
3 (32) Gattazzo, F.; De Maria, C.; Rimessi, A.; Dona, S.; Braghetta, P.; Pinton, P.; Vozi, G.;
4 Bonaldo, P. Gelatin-Genipin-Based Biomaterials for Skeletal Muscle Tissue Engineering.
5 *J. Biomed. Mater. Res. B. Appl. Biomater.* **2018**, *106* (8), 2763–2777.
6 <https://doi.org/10.1002/jbm.b.34057>.
7
- 8 (33) Szili, S. E. M. and A. T. A. J. and S. A. A.-B. and R. D. S. and S.-H. H. and N. T. T. and J.-S.
9 O. and J. W. B. and E. J. Studying the Cytolytic Activity of Gas Plasma with Self-Signalling
10 Phospholipid Vesicles Dispersed within a Gelatin Matrix. *J. Phys. D. Appl. Phys.* **2013**, *46*
11 (18), 185401.
12
- 13 (34) Short, E. J. S. and J. W. B. and R. D. A ‘Tissue Model’ to Study the Plasma Delivery of
14 Reactive Oxygen Species. *J. Phys. D. Appl. Phys.* **2014**, *47* (15), 152002.
15
- 16 (35) Gaur, N.; Szili, E. J.; Oh, J.-S.; Hong, S.-H.; Michelmores, A.; Graves, D. B.; Hatta, A.; Short,
17 R. D. Combined Effect of Protein and Oxygen on Reactive Oxygen and Nitrogen Species
18 in the Plasma Treatment of Tissue. *Appl. Phys. Lett.* **2015**, *107* (10), 103703.
19 <https://doi.org/10.1063/1.4930874>.
20
- 21 (36) Short, E. J. S. and J.-S. O. and S.-H. H. and A. H. and R. D. Probing the Transport of
22 Plasma-Generated RONS in an Agarose Target as Surrogate for Real Tissue: Dependency
23 on Time, Distance and Material Composition. *J. Phys. D. Appl. Phys.* **2015**, *48* (20),
24 202001.
25
- 26 (37) Szili, E. J.; Hong, S.-H.; Short, R. D. On the Effect of Serum on the Transport of Reactive
27 Oxygen Species across Phospholipid Membranes. *Biointerphases* **2015**, *10* (2), 29511.
28 <https://doi.org/10.1116/1.4918765>.
29
- 30 (38) Zaplotnik, R.; Biščan, M.; Kregar, Z.; Cvelbar, U.; Mozetič, M.; Milošević, S. Influence of a
31 Sample Surface on Single Electrode Atmospheric Plasma Jet Parameters. *Spectrochim.*
32 *Acta Part B At. Spectrosc.* **2015**, *103–104*, 124–130.
33 <https://doi.org/https://doi.org/10.1016/j.sab.2014.12.004>.
34
- 35 (39) Reuter, S.; von Woedtke, T.; Weltmann, K.-D. The KINPen—a Review on Physics and
36 Chemistry of the Atmospheric Pressure Plasma Jet and Its Applications. *J. Phys. D. Appl.*
37 *Phys.* **2018**, *51* (23), 233001.
38
- 39 (40) Guevara, I.; Iwanejko, J.; Dembinska-Kiec, A.; Pankiewicz, J.; Wanat, A.; Anna, P.;
40 Golabek, I.; Bartus, S.; Malczewska-Malec, M.; Szczudlik, A. Determination of
41 Nitrite/Nitrate in Human Biological Material by the Simple Griess Reaction. *Clin. Chim.*
42 *Acta.* **1998**, *274* (2), 177–188.
43
- 44 (41) Giustarini, D.; Rossi, R.; Milzani, A.; Dalle-Donne, I. Nitrite and Nitrate Measurement by
45 Griess Reagent in Human Plasma: Evaluation of Interferences and Standardization.
46 *Methods Enzymol.* **2008**, *440*, 361–380. [https://doi.org/10.1016/S0076-6879\(07\)00823-](https://doi.org/10.1016/S0076-6879(07)00823-3)
47 [3](https://doi.org/10.1016/S0076-6879(07)00823-3).
48
- 49 (42) Kaushik, N. K.; Ghimire, B.; Li, Y.; Adhikari, M.; Veerana, M.; Kaushik, N.; Jha, N.;
50 Adhikari, B.; Lee, S.-J.; Masur, K.; von Woedtke, T.; Weltmann, K.-D.; Choi, E. H.
51 Biological and Medical Applications of Plasma-Activated Media, Water and Solutions.
52 *Biol. Chem.* **2018**, *400* (1), 39–62. <https://doi.org/10.1515/hsz-2018-0226>.
53
- 54 (43) Azzariti, A.; Iacobazzi, R. M.; Di Fonte, R.; Porcelli, L.; Gristina, R.; Favia, P.; Fracassi, F.;
55 Trizio, I.; Silvestris, N.; Guida, G.; Tommasi, S.; Sardella, E. Plasma-Activated Medium
56 Triggers Cell Death and the Presentation of Immune Activating Danger Signals in
57 Melanoma and Pancreatic Cancer Cells. *Sci. Rep.* **2019**, *9* (1), 4099.
58 <https://doi.org/10.1038/s41598-019-40637-z>.
59
60

- 1
2
3 (44) Liedtke, K. R.; Bekeschus, S.; Kaeding, A.; Hackbarth, C.; Kuehn, J.-P.; Heidecke, C.-D.;
4 von Bernstorff, W.; von Woedtke, T.; Partecke, L. I. Non-Thermal Plasma-Treated
5 Solution Demonstrates Antitumor Activity against Pancreatic Cancer Cells in Vitro and in
6 Vivo. *Sci. Rep.* **2017**, *7* (1), 8319. <https://doi.org/10.1038/s41598-017-08560-3>.
7
- 8 (45) Mateu-Sanz, M.; Tornín, J.; Brulin, B.; Khlyustova, A.; Ginebra, M.-P.; Layrolle, P.; Canal,
9 C. Cold Plasma-Treated Ringer's Saline: A Weapon to Target Osteosarcoma. *Cancers*
10 (*Basel*). **2020**, *12* (1), 227. <https://doi.org/10.3390/cancers12010227>.
11
- 12 (46) Yan, D.; Wang, Q.; Adhikari, M.; Malyavko, A.; Lin, L.; Zolotukhin, D.; Yao, X.; Kirschner,
13 M.; Sherman, J. H.; Keidar, M. A Physically Triggered Cell Death via Transbarrier Cold
14 Atmospheric Plasma Cancer Treatment. *ACS Appl. Mater. Interfaces* **2020**.
15 <https://doi.org/10.1021/acsami.0c06500>.
16
- 17 (47) Gjika, E.; Pal-Ghosh, S.; Tang, A.; Kirschner, M.; Tadvalkar, G.; Canady, J.; Stepp, M. A.;
18 Keidar, M. Adaptation of Operational Parameters of Cold Atmospheric Plasma for in
19 Vitro Treatment of Cancer Cells. *ACS Appl. Mater. Interfaces* **2018**, *10* (11), 9269–9279.
20 <https://doi.org/10.1021/acsami.7b18653>.
21
- 22 (48) Xu, J.; Feng, Q.; Lin, S.; Yuan, W.; Li, R.; Li, J.; Wei, K.; Chen, X.; Zhang, K.; Yang, Y.; Wu,
23 T.; Wang, B.; Zhu, M.; Guo, R.; Li, G.; Bian, L. Injectable Stem Cell-Laden Supramolecular
24 Hydrogels Enhance in Situ Osteochondral Regeneration via the Sustained Co-Delivery of
25 Hydrophilic and Hydrophobic Chondrogenic Molecules. *Biomaterials* **2019**.
26 <https://doi.org/https://doi.org/10.1016/j.biomaterials.2019.04.031>.
27
- 28 (49) Feng, Q.; Wei, K.; Lin, S.; Xu, Z.; Sun, Y.; Shi, P.; Li, G.; Bian, L. Mechanically Resilient,
29 Injectable, and Bioadhesive Supramolecular Gelatin Hydrogels Crosslinked by Weak
30 Host-Guest Interactions Assist Cell Infiltration and in Situ Tissue Regeneration.
31 *Biomaterials* **2016**, *101*, 217–228.
32 <https://doi.org/https://doi.org/10.1016/j.biomaterials.2016.05.043>.
33
- 34 (50) Kong, T. H. and D. L. and H. X. and Z. liu and D. X. and D. L. and Q. L. and M. R. and M. G.
35 A 'Tissue Model' to Study the Barrier Effects of Living Tissues on the Reactive Species
36 Generated by Surface Air Discharge. *J. Phys. D. Appl. Phys.* **2016**, *49* (20), 205204.
37
- 38 (51) Oh, J.-S.; Szili, E. J.; Ito, S.; Hong, S.-H.; Gaur, N.; Furuta, H.; Short, R. D.; Hatta, A. Slow
39 Molecular Transport of Plasma-Generated Reactive Oxygen and Nitrogen Species and
40 O₂ through Agarose as a Surrogate for Tissue. *Plasma Med.* **2015**.
41 <https://doi.org/10.1615/PlasmaMed.2016015740>.
42
- 43 (52) Oh, J.-S.; Szili, E. J.; Gaur, N.; Hong, S.-H.; Furuta, H.; Kurita, H.; Mizuno, A.; Hatta, A.;
44 Short, R. D. How to Assess the Plasma Delivery of RONS into Tissue Fluid and Tissue. *J.*
45 *Phys. D. Appl. Phys.* **2016**, *49* (30), 304005. [https://doi.org/10.1088/0022-](https://doi.org/10.1088/0022-3727/49/30/304005)
46 [3727/49/30/304005](https://doi.org/10.1088/0022-3727/49/30/304005).
47
- 48 (53) Kawasaki, T.; Sato, A.; Kusumegi, S.; Kudo, A.; Sakanoshita, T.; Tsurumaru, T.; Uchida,
49 G.; Koga, K.; Shiratani, M. Two-Dimensional Concentration Distribution of Reactive
50 Oxygen Species Transported through a Tissue Phantom by Atmospheric-Pressure
51 Plasma-Jet Irradiation. *Appl. Phys. Express* **2016**, *9* (7), 76202.
52 <https://doi.org/10.7567/apex.9.076202>.
53
- 54 (54) Oh, J.-S.; Szili, E. J.; Gaur, N.; Hong, S.-H.; Furuta, H.; Short, R. D.; Hatta, A. In-Situ UV
55 Absorption Spectroscopy for Monitoring Transport of Plasma Reactive Species through
56 Agarose as Surrogate for Tissue. *J. Photopolym. Sci. Technol.* **2015**, *28* (3), 439–444.
57 <https://doi.org/10.2494/photopolymer.28.439>.
58
59
60

- 1
2
3 (55) Khlyustova, A.; Labay, C.; Machala, Z.; Ginebra, M.-P.; Canal, C. Important Parameters in
4 Plasma Jets for the Production of RONS in Liquids for Plasma Medicine: A Brief Review.
5 *Front. Chem. Sci. Eng.* **2019**. <https://doi.org/10.1007/s11705-019-1801-8>.
6
7 (56) Chen, Z.; Simonyan, H.; Cheng, X.; Gjika, E.; Lin, L.; Canady, J.; Sherman, J. H.; Young, C.;
8 Keidar, M. A Novel Micro Cold Atmospheric Plasma Device for Glioblastoma Both in
9 Vitro and in Vivo. *Cancers (Basel)*. **2017**. <https://doi.org/10.3390/cancers9060061>.
10
11 (57) Attri, P.; Yusupov, M.; Park, J. H.; Lingamdinne, L. P.; Koduru, J. R.; Shiratani, M.; Choi, E.
12 H.; Bogaerts, A. Mechanism and Comparison of Needle-Type Non-Thermal Direct and
13 Indirect Atmospheric Pressure Plasma Jets on the Degradation of Dyes. *Sci. Rep.* **2016**.
14 <https://doi.org/10.1038/srep34419>.
15
16 (58) Oh, J.-S.; Szili, E. J.; Ogawa, K.; Short, R. D.; Ito, M.; Furuta, H.; Hatta, A. UV–Vis
17 Spectroscopy Study of Plasma-Activated Water: Dependence of the Chemical
18 Composition on Plasma Exposure Time and Treatment Distance. *Jpn. J. Appl. Phys.*
19 **2018**, *57* (1), 0102B9. <https://doi.org/10.7567/JJAP.57.0102B9>.
20
21 (59) Labay, Cédric; Hamouda, Inès; Tampieri, Francesco; Ginebra, Maria-Pau; Canal, C.
22 Production of Reactive Species in Alginate Hydrogels for Cold Atmospheric Plasma-
23 Based Therapies. *Sci. Rep.* **2019**.
24
25 (60) Vlad, I.-E.; Anghel, S. D. Time Stability of Water Activated by Different On-Liquid
26 Atmospheric Pressure Plasmas. *J. Electrostat.* **2017**, *87*, 284–292.
27 <https://doi.org/https://doi.org/10.1016/j.elstat.2017.06.002>.
28
29 (61) Zhou, R.; Zhou, R.; Prasad, K.; Fang, Z.; Speight, R.; Bazaka, K.; Ostrikov, K. (Ken). Cold
30 Atmospheric Plasma Activated Water as a Prospective Disinfectant: The Crucial Role of
31 Peroxynitrite. *Green Chem.* **2018**, *20* (23), 5276–5284.
32 <https://doi.org/10.1039/C8GC02800A>.
33
34 (62) Abuzairi, T.; Ramadhanty, S.; Puspohadiningrum, D. F.; Ratnasari, A.; Poespawati, N. R.;
35 Purnamaningsih, R. W. Investigation on Physicochemical Properties of Plasma-Activated
36 Water for the Application of Medical Device Sterilization. *AIP Conf. Proc.* **2018**, *1933* (1),
37 40017. <https://doi.org/10.1063/1.5023987>.
38
39 (63) Bosi, F. J.; Tampieri, F.; Marotta, E.; Bertani, R.; Pavarin, D.; Paradisi, C. Characterization
40 and Comparative Evaluation of Two Atmospheric Plasma Sources for Water Treatment.
41 *Plasma Process. Polym.* **2018**, *15* (3), 1700130.
42 <https://doi.org/10.1002/ppap.201700130>.
43
44 (64) Clupek, P. L. and E. D. and I. S. and M. Aqueous-Phase Chemistry and Bactericidal
45 Effects from an Air Discharge Plasma in Contact with Water: Evidence for the Formation
46 of Peroxynitrite through a Pseudo-Second-Order Post-Discharge Reaction of H₂O₂
47 and HNO₂. *Plasma Sources Sci. Technol.* **2014**, *23* (1), 15019.
48
49 (65) Tosh, S. M.; Marangoni, A. G. Determination of the Maximum Gelation Temperature in
50 Gelatin Gels. *Appl. Phys. Lett.* **2004**, *84* (21), 4242–4244.
51 <https://doi.org/10.1063/1.1756210>.
52
53 (66) Reuter, S.; von Woedtke, T.; Weltmann, K.-D. The KINPen—a Review on Physics and
54 Chemistry of the Atmospheric Pressure Plasma Jet and Its Applications. *J. Phys. D: Appl.*
55 *Phys.* **2018**, *51* (23), 233001.
56
57 (67) Stancampiano, A.; Simoncelli, E.; Boselli, M.; Colombo, V.; Gherardi, M. Experimental
58 Investigation on the Interaction of a Nanopulsed Plasma Jet with a Liquid Target.
59
60

- 1
2
3 *Plasma Sources Sci. Technol.* **2018**, 27 (12), 125002. <https://doi.org/10.1088/1361-6595/aae9d0>.
- 4
5
6 (68) Ungate, C.; Harleman, D.; Jirka, G. Stability and Mixing of Submerged Turbulent Jets at
7 Low Reynolds Numbers. *MIT Dep Civ Eng Ralph M, Parsons Lab Water Resour Hydrodyn*
8 *Rep* **1975**.
- 9
10 (69) Persi, E.; Duran-Frigola, M.; Damaghi, M.; Roush, W. R.; Aloy, P.; Cleveland, J. L.; Gillies,
11 R. J.; Ruppin, E. Systems Analysis of Intracellular PH Vulnerabilities for Cancer Therapy.
12 *Nat. Commun.* **2018**, 9 (1), 2997. <https://doi.org/10.1038/s41467-018-05261-x>.
- 13
14 (70) Schulze, A.; Harris, A. L. How Cancer Metabolism Is Tuned for Proliferation and
15 Vulnerable to Disruption. *Nature* **2012**, 491, 364.
- 16
17 (71) Webb, B. A.; Chimenti, M.; Jacobson, M. P.; Barber, D. L. Dysregulated PH: A Perfect
18 Storm for Cancer Progression. *Nat. Rev. Cancer* **2011**, 11, 671.
- 19
20 (72) Gatenby, R. A.; Gillies, R. J. Why Do Cancers Have High Aerobic Glycolysis? *Nat. Rev.*
21 *Cancer* **2004**, 4 (11), 891–899. <https://doi.org/10.1038/nrc1478>.
- 22
23 (73) Gatenby, R. A.; Gawlinski, E. T.; Gmitro, A. F.; Kaylor, B.; Gillies, R. J. Acid-Mediated
24 Tumor Invasion: A Multidisciplinary Study. *Cancer Res.* **2006**, 66 (10), 5216 LP – 5223.
25 <https://doi.org/10.1158/0008-5472.CAN-05-4193>.
- 26
27 (74) Robey, I. F.; Baggett, B. K.; Kirkpatrick, N. D.; Roe, D. J.; Dosesescu, J.; Sloane, B. F.;
28 Hashim, A. I.; Morse, D. L.; Raghunand, N.; Gatenby, R. A.; Gillies, R. J. Bicarbonate
29 Increases Tumor PH and Inhibits Spontaneous Metastases. *Cancer Res.* **2009**, 69 (6),
30 2260 LP – 2268. <https://doi.org/10.1158/0008-5472.CAN-07-5575>.
- 31
32 (75) McCarty, M. F.; Whitaker, J. Manipulating Tumor Acidification as a Cancer Treatment
33 Strategy. *Altern. Med. Rev.* **2010**, 15 (3), 264–272.
- 34
35 (76) Hoentsch, M.; Bussiahn, R.; Rebl, H.; Bergemann, C.; Eggert, M.; Frank, M.; von
36 Woedtke, T.; Nebe, B. Persistent Effectivity of Gas Plasma-Treated, Long Time-Stored
37 Liquid on Epithelial Cell Adhesion Capacity and Membrane Morphology. *PLoS One* **2014**,
38 9 (8), e104559.
- 39
40 (77) Semmler, M. L.; Bekeschus, S.; Schäfer, M.; Bernhardt, T.; Fischer, T.; Witzke, K.;
41 Seebauer, C.; Rebl, H.; Grambow, E.; Vollmar, B.; Nebe, J. B.; Metelmann, H.-R.;
42 Woedtke, T. von; Emmert, S.; Boeckmann, L. Molecular Mechanisms of the Efficacy of
43 Cold Atmospheric Pressure Plasma (CAP) in Cancer Treatment. *Cancers (Basel)*. **2020**, 12
44 (2), 269. <https://doi.org/10.3390/cancers12020269>.
- 45
46 (78) Laroussi, M. Effects of PAM on Select Normal and Cancerous Epithelial Cells. *Plasma*
47 *Res. Express* **2019**, 1 (2), 25010. <https://doi.org/10.1088/2516-1067/ab1b8a>.
- 48
49 (79) Xiang, L.; Xu, X.; Zhang, S.; Cai, D.; Dai, X. Cold Atmospheric Plasma Conveys Selectivity
50 on Triple Negative Breast Cancer Cells Both in Vitro and in Vivo. *Free Radic. Biol. Med.*
51 **2018**, 124, 205–213. <https://doi.org/10.1016/j.freeradbiomed.2018.06.001>.
- 52
53
54
55
56
57
58
59
60

1
2
3 **All authors** have approved the submitted version;
4

5 **All authors** have agreed both to be personally accountable for the author's own contributions
6 and to ensure that questions related to the accuracy or integrity of any part of the work, even
7 ones in which the author was not personally involved, are appropriately investigated, resolved,
8 and the resolution documented in the literature.
9

10
11
12
13 **Declaration of interests**
14

15 Following the competing interests statement guidelines of the publication, the authors declare
16 no competing interests.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60